

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use

TITLE VI **U.K.**

CLASSIFICATION OF MEDICINAL PRODUCTS

Article 71 **U.K.**

- 1 Medicinal products shall be subject to medical prescription where they:
 - are likely to present a danger either directly or indirectly, even when used correctly, if utilized without medical supervision, or
 - are frequently and to a very wide extent used incorrectly, and as a result are likely to present a direct or indirect danger to human health, or
 - contain substances or preparations thereof, the activity and/or adverse reactions of which require further investigation, or
 - are normally prescribed by a doctor to be administered parenterally.
- 2 Where Member States provide for the sub-category of medicinal products subject to special medical prescription, they shall take account of the following factors:
 - the medicinal product contains, in a non-exempt quantity, a substance classified as a narcotic or a psychotropic substance within the meaning of the international conventions in force, such as the United Nations Conventions of 1961 and 1971, or
 - the medicinal product is likely, if incorrectly used, to present a substantial risk of medicinal abuse, to lead to addiction or be misused for illegal purposes, or
 - the medicinal product contains a substance which, by reason of its novelty or properties, could be considered as belonging to the group envisaged in the second indent as a precautionary measure.
- 3 Where Member States provide for the sub-category of medicinal products subject to restricted prescription, they shall take account of the following factors:
 - the medicinal product, because of its pharmaceutical characteristics or novelty or in the interests of public health, is reserved for treatments which can only be followed in a hospital environment,
 - the medicinal product is used in the treatment of conditions which must be diagnosed in a hospital environment or in institutions with adequate diagnostic facilities, although administration and follow-up may be carried out elsewhere, or
 - the medicinal product is intended for outpatients but its use may produce very serious adverse reactions requiring a prescription drawn up as required by a specialist and special supervision throughout the treatment.
- 4 A competent authority may waive application of paragraphs 1, 2 and 3 having regard to:
 - a the maximum single dose, the maximum daily dose, the strength, the pharmaceutical form, certain types of packaging; and/or
 - b other circumstances of use which it has specified.
- 5 If a competent authority does not designate medicinal products into sub-categories referred to in Article 70(2), it shall nevertheless take into account the criteria referred to in

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

paragraphs 2 and 3 of this Article in determining whether any medicinal product shall be classified as a prescription-only medicine.